Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216481 | 0.84 | HSD11B1 (0.53) | HSD11B1MEN1KMT2AP2RX7 | |
| SCHEMBL13216484 | 0.83 | HSD11B1 (0.64) | HSD11B1EPHX2HPGDP2RX7MAPK1 | |
| SCHEMBL13216317 | 0.80 | HSD11B1 (0.67) | HSD11B1EPHX2MEN1KMT2AP2RX7 | |
| SCHEMBL13216325 | 0.77 | HSD11B1 (1.00) | HSD11B1EPHX2MEN1KMT2AHPGD | |
| SCHEMBL17356681 | 0.77 | HSD11B1 (0.58) | HSD11B1EPHX2MEN1KMT2AHPGD | |
| SCHEMBL17082681 | 0.75 | HSD11B1 (0.44) | HSD11B1MEN1KMT2AHPGDCYP3A4 | |
| SCHEMBL15922992 | 0.73 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL15922990 | 0.73 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL14300035 | 0.71 | HSD11B1 (0.52) | HSD11B1EPHX2MEN1KMT2AHPGD | |
| SCHEMBL7057795 | 0.70 | HSD11B1 (0.51) | HSD11B1EPHX2MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054368-B1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299054-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727978-B2 | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2054368-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-25 | — | — | US | disclosed |
| WO-2008024892-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024892-A2 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234249-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 650/4885MEN1 994/4885 |
| US-20100204199-A1 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 650/4885MEN1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.